Regenerative Medicine Is Here: New Payment Models Key To Patient Access
Moving From Chronic Therapies To Cures - Creating A Pathway To Enable New Payment Models
Potentially curative regenerative medicine therapies are no longer theoretical, but instead have become reality. As more and more gene, cell and tissue-based therapies reach the market, the need for payment solutions is becoming more pressing. The Alliance for Regenerative Medicine has consulted with payers and other stakeholders to consider the barriers to alternative payment models and look at possible solutions.
You may also be interested in...
Final guidance on drug manufacturer communications with payors adopts industry call to include exchanges about unapproved uses; they will not be considered evidence of intended use.
Otherwise, CMS proposes pegging inpatient hospital reimbursement for CAR-T treatment to bundled rate for bone marrow transplants and potentially providing add-on payments for at least a couple of years.
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.